Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63

Bone

Volumn 55, Issue 2, 2013, Pages 432-438

  Liu, Lifeng ^a   Xu, Ying ^b   Reiter, Russel J ^c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cell cycle; Melatonin; MG 63; Osteosarcoma; Proliferation

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; MELATONIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOCHEMISTRY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; OSTEOSARCOMA; PHASE TRANSITION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TIME; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MELATONIN; OSTEOSARCOMA; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84878950558     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.02.021     Document Type: Article

References (56)

1. Mirabello L., Troisi R.J., Savage S.A. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009, 125:229-234.
2. Withrow S.J., Powers B.E., Straw R.C., Wilkins R.M. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res 1991, 270:159-168.
3. Cotterill S.J., Wright C.M., Pearce M.S. Craft AW; UKCCSG/MRC Bone Tumour Working Group. Stature of young people with malignant bone tumors. Pediatr Blood Cancer 2004, 42:59-63.
4. Marina N., Gebhardt M., Teot L., Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422-441.
5. Gelberg K.H., Fitzgerald E.F., Hwang S., Dubrow R. Growth and development and other risk factors for osteosarcoma in children and young adults. Int J Epidemiol 1997, 26:272-278.
6. Longhi A., Pasini A., Cicognani A., Baronio F., Pellacani A., Baldini N., et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol 2005, 27:314-318.
7. Mirabello L., Pfeiffer R., Murphy G., Daw N.C., Patiño-Garcia A., Troisi R.J., et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control 2011, 22:899-908.
8. Sánchez-Barceló E.J., Mediavilla M.D., Tan D.X., Reiter R.J. Scientific basis for the potential use of melatonin in bone diseases: osteoporosis and adolescent idiopathic scoliosis. J Osteoporos 2010, 2010:830231.
9. Stehle J.H., Saade A., Rawashdeh O., Ackermann K., Jilg A., Sebestény T., et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011, 51:17-43.
10. Reiter R.J., Paredes S.D., Manchester L.C., Tan D.X. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009, 44:175-200.
11. Cardinali D.P., Ladizesky M.G., Boggio V., Cutrera R.A., Mautalen C. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003, 34:81-87.
12. Liu L., Zhu Y., Xu Y., Reiter R.J. Melatonin delays cell proliferation by inducing G1 and G2 /M phase arrest in a human osteoblastic cell line hFOB 1.19. J Pineal Res 2011, 50:222-231.
13. Kotlarczyk M.P., Lassila H.C., O'Neil C.K., D'Amico F., Enderby L.T., Witt-Enderby P.A., et al. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res 2012, 52:414-426.
14. Clafshenkel W.P., Rutkowski J.L., Palchesko R.N., Romeo J.D., McGowan K.A., Gawalt E.S., et al. A novel calcium aluminate-melatonin scaffold enhances bone regeneration within a calvarial defect. J Pineal Res 2012, 53:206-218.
15. Conti A., Conconi S., Hertens E., Skwarlo-Sonta K., Markowska M., Maestroni J.M. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000, 28:193-202.
16. Tan D.X., Manchester L.C., Reiter R.J., Qi W.B., Zhang M., Weintraub S.T., et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999, 1472:206-214.
17. Cos S., Sánchez-Barceló E.J. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000, 21:133-170.
18. Wang J., Xiao X., Zhang Y., Shi D., Chen W., Fu L., et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012, 53:77-90.
19. Sánchez-Hidalgo M., Lee M., de la Lastra C.A., Guerrero J.M., Packham G. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J Pineal Res 2012, 53:366-373.
20. Petranka J., Baldwin W., Biermann J., Jayadev S., Barrett J.C., Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999, 26:129-136.
21. Kanishi Y., Kobayashi Y., Noda S., Ishizuka B., Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 2000, 28:227-233.
22. Hu D.N., Roberts J.E. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res 1997, 7:27-31.
23. Gilad E., Laufer M., Matzkin H., Zisapel N. Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res 1999, 26:211-220.
24. Anisimov V.N., Popovich I.G., Zabezhinski M.A. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 1997, 18:1549-1553.
25. Subramanian P., Mirunalini S., Dakshayani K.B., Pandi-Perumal S.R., Trakht I., Cardinali D.P. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. J Pineal Res 2007, 43:305-312.
26. Mills E., Wu P., Seely D., Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005, 39:360-366.
27. Reiter R.J., Tan D.X., Sainz R.M., Mayo J.C., Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002, 54:1299-1321.
28. Wang Y.M., Jin B.Z., Ai F., Duan C.H., Lu Y.Z., Dong T.F., et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 2012, 69:1213-1220.
29. Xu Y., Liu L., Qiu X., Jiang L., Huang B., Li H., et al. CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells. PLoS One 2011, 6:e21119.
30. Pizarro J.G., Yeste-Velasco M., Esparza J.L., Verdaguer E., Pallàs M., Camins A., et al. The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes. J Pineal Res 2008, 45:8-16.
31. Datta N.S., Pettway G.J., Chen C., Koh A.J., McCauley L.K. Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 2007, 22:951-964.
32. Reiter R.J., Tan D.X., Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res 2010, 181:127-151.
33. Lissoni P., Barni S., Mandalà M., Ardizzoia A., Paolorossi F., Vaghi M., et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999, 35:1688-1692.
34. Lissoni P. Is there a role for melatonin in supportive care?. Support Care Cancer 2002, 10:110-116.
35. Kim C., Kim N., Joo H., Youm J.B., Park W.S., Cuong D.V., et al. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 2005, 46:200-210.
36. Dziegiel P., Podhorska-Okolow M., Zabel M. Melatonin: adjuvant therapy of malignant tumors. Med Sci Monit 2008, 14:64-70.
37. Pandi-Perumal S.R., Trakht I., Srinivasan V., Spence D.W., Maestroni G.J., Zisapel N., et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008, 85:335-353.
38. Panzer A., Lottering M.L., Bianchi P., Glencross D.K., Stark J.H., Seegers J.C. Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett 1998, 122:17-23.
39. Nigg E.A. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 1995, 17:471-480.
40. Knoblich J.A., Sauer K., Jones L., Richardson H., Saint R., Lehner C.F. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell 1994, 77:107-120.
41. Ohtsubo M., Roberts J.M. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993, 259:1908-1912.
42. Girard F., Strausfeld U., Fernandez A., Lamb N.J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991, 67:1169-1179.
43. Pagano M., Pepperkok R., Verde F., Ansorge W., Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992, 11:961-971.
44. King R.W., Jackson P.K., Kirschner M.W. Mitosis in transition. Cell 1994, 79:563-571.
45. Knoblich J.A., Lehner C.F. Synergistic action of Drosophila cyclins A and B during the G2-M transition. EMBO J 1993, 12:65-74.
46. Tajes Orduña M., Pelegrí Gabalda C., Vilaplana Hortensi J., Pallàs Lliberia M., Camins Espuny A. An evaluation of the neuroprotective effects of melatonin in an in vitro experimental model of age-induced neuronal apoptosis. J Pineal Res 2009, 46:262-267.
47. Gu X., Xing L., Shi G., Liu Z., Wang X., Qu Z., et al. The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ 2012, 19:397-405.
48. Ripperger J.A., Schmutz I., Albrecht U. PERsuading nuclear receptors to dance the circadian rhythm. Cell Cycle 2010, 9:2515-2521.
49. Dubocovich M.L., Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27:101-110.
50. Toma C.D., Svoboda M., Arrich F., Ekmekcioglu C., Assadian O., Thalhammer T. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. J Pineal Res 2007, 43:206-213.
51. Cui P., Yu M., Luo Z., Dai M., Han J., Xiu R., et al. Intracellular signaling pathways involved in cell growth inhibition of human umbilical vein endothelial cells by melatonin. J Pineal Res 2008, 44:107-114.
52. Nah S.S., Won H.J., Park H.J., Ha E., Chung J.H., Cho H.Y., et al. Melatonin inhibits human fibroblast-like synoviocyte proliferation via extracellular signal-regulated protein kinase/P21(CIP1)/P27(KIP1) pathways. J Pineal Res 2009, 47:70-74.
53. Martín-Renedo J., Mauriz J.L., Jorquera F., Ruiz-Andrés O., González P., González-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008, 45:532-540.
54. Cabrera J., Negrín G., Estévez F., Loro J., Reiter R.J., Quintana J. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010, 49:45-54.
55. Martín V., Herrera F., Carrera-Gonzalez P., García-Santos G., Antolín I., Rodriguez-Blanco J., et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006, 66:1081-1088.
56. Proietti S., Cucina A., D'Anselmi F., Dinicola S., Pasqualato A., Lisi E., et al. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 2011, 50:150-158.